Swedencare AB (publ) (OTCMKTS:SWDCF – Get Free Report) and Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.
Valuation and Earnings
This table compares Swedencare AB (publ) and Zevra Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Swedencare AB (publ) | N/A | N/A | N/A | N/A | N/A |
| Zevra Therapeutics | $106.47 million | 6.63 | $83.23 million | $0.92 | 12.92 |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Swedencare AB (publ) and Zevra Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Swedencare AB (publ) | 0 | 0 | 0 | 0 | 0.00 |
| Zevra Therapeutics | 0 | 1 | 9 | 0 | 2.90 |
Zevra Therapeutics has a consensus price target of $27.14, suggesting a potential upside of 128.28%. Given Zevra Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Swedencare AB (publ).
Institutional & Insider Ownership
35.0% of Zevra Therapeutics shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Swedencare AB (publ) and Zevra Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Swedencare AB (publ) | N/A | N/A | N/A |
| Zevra Therapeutics | 42.82% | 54.54% | 34.15% |
Summary
Zevra Therapeutics beats Swedencare AB (publ) on 9 of the 9 factors compared between the two stocks.
About Swedencare AB (publ)
-logo-1200x675.png){kind=logo}
Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells animal healthcare products for cats, dogs, and horses in Sweden, the United Kingdom, Rest of Europe, North America, Asia, and internationally. It offers products and solutions for the pets wellbeing under the Camon name; animal nutritional supplements, treats, and grooming products under the Healthy Breeds name; pet supplements and topical products for various therapeutic areas, such as orthopedics, behavior, dermatology, odontostomatology, algology, gastroenterology, urology, nephrology, and ophthalmology under the Innovet name; and support and solutions for the veterinary community under the Stratford Animal Health name. The company also provides pet health supplements under the NaturVet, VETCLASSICS, and NutriScience name; pet supplements, vitamins, dental care, ear cleaners, pilling agents, and topicals under the Pet MD name; and vet-formulated pet care products under the VetWELL name. In addition, it offers ProDen PlaqueOff powder, a solution for pet oral problems; ProDen PlaqueOff dental bones; ProDen PlaqueOff dental bites, a pet dental product; and Rx Vitamins for Pets. The company distributes its products through veterinarians, pet stores, and online. Swedencare AB (publ) was incorporated in 1993 and is headquartered in Malmö, Sweden.
About Zevra Therapeutics
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Receive News & Ratings for Swedencare AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedencare AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
